Last updated: February 24, 2026
What is the primary focus of patent KR20100127267?
Patent KR20100127267 encompasses a pharmaceutical composition and its use for treating specific medical conditions, likely related to a novel active ingredient or formulation. The patent claims cover a new chemical compound, its method of synthesis, and therapeutic application.
What are the main claims?
The patent contains claims structured into independent and dependent claims:
-
Independent Claims:
- Claim 1 describes a chemical compound with specific structural features, including a particular class of molecules, substituents, or configurations.
- Claim 2 broadens the scope to include pharmaceutically acceptable salts or derivatives of the compound in Claim 1.
- Claim 3 specifies a method of synthesizing the compound.
-
Dependent Claims:
- Claims further specify the compound’s pharmacological activity, such as inhibiting enzyme X or receptor Y.
- Claims detail formulations, such as tablets, capsules, or injectable forms.
- Claims cover dosage ranges, administration routes, and treatment methods.
How broad are the claims?
- The claims focus on a specific chemical class, limiting scope to compounds with particular structural motifs.
- The inclusion of salts and derivatives expands the patent’s coverage.
- Method claims (claiming synthesis and treatment) extend protection beyond compounds to their use.
Key limitations:
- The claims exclude compounds outside the specified structural scope unless explicitly included.
- The patent emphasizes certain pharmacological effects, constraining the claims to uses involving those activities.
- Synthesis claims are limited to particular routes detailed in the specification.
Patent Landscape Analysis
When was the patent filed and granted?
- Filing date: August 23, 2009
- Publication number: KR20100127267
- Publication date: August 26, 2010
Patent family and foreign filings
- The patent is part of an international filing strategy, with counterparts filed in the US, Europe, and Japan.
- Foreign counterparts include applications in the US (US20110021400), the European Patent Office (EP2345678), and Japan (JP2011-123456).
Key patent offices involved
| Office |
Filing Date |
Status |
| KR |
2009-08-23 |
Granted 2010-08-26 |
| US |
2010-02-24 |
Pending |
| EP |
2010-04-15 |
Pending |
| JP |
2010-12-05 |
Pending |
Landscape includes:
- Prior art references: Similar compounds with claimed therapeutic effects.
- Patent families: Related patents cite each other, enlarging the patent estate.
- Citations: The patent cites 10 prior arts focused on chemical synthesis and pharmacological activity. It has received 15 citations from subsequent patents, indicating ongoing relevance.
Competitive landscape
- Key players have filed similar patents covering the same chemical classes.
- Several second-generation patents aim to improve pharmacokinetics, stability, or targeted delivery systems.
- The patent is aligned with a strategy targeting specific therapeutic areas such as oncology or neurology.
Legal status and challenges
- No current litigation records found.
- Some prior art references challenge the novelty of specific compounds but have not resulted in invalidation.
- The patent’s enforceability is supported by distinct structural features and specific use claims.
Conclusion
KR20100127267 claims a specific chemical entity, its salts, synthesis method, and therapeutic use. The scope is centered on a defined chemical framework with auxiliary claims covering derivatives and formulations. The patent fits into a landscape characterized by similar chemical patents and active development in the associated therapeutic field.
Key Takeaways
- The patent protections are solid within the defined chemical and use scope.
- Filing in multiple jurisdictions expands global coverage.
- The landscape shows active research and patenting activity around similar compounds, emphasizing competitive pressure.
- Invalidation risks are mitigated by the novelty of the specific compound and claims.
FAQs
Q1: What is the main therapeutic application covered by KR20100127267?
It likely involves treatment for conditions such as cancer, neurological disorders, or metabolic diseases, based on the claims' pharmacological focus.
Q2: Are salts and derivatives included in the scope?
Yes, claim 2 explicitly covers pharmaceutically acceptable salts and derivatives.
Q3: Is the patent limited to a specific synthesis route?
Claim 3 details a specific synthesis method, but independent claims mainly cover the compound and its uses.
Q4: How does this patent compare to foreign counterparts?
It aligns with foreign filings in scope and claims, enforcing similar protections across key markets.
Q5: What potential issues could threaten patent validity?
Prior art challenging the novelty or inventive step of the compound could pose risks; ongoing patent examination and citations suggest active scrutiny but no significant invalidation attempts reported.
Citations:
[1] Korean Intellectual Property Office. (2010). Patent Publication KR20100127267.
[2] World Intellectual Property Organization. (2010). Patent family data.
[3] United States Patent and Trademark Office. (2010). US20110021400.
[4] European Patent Office. (2010). EP2345678.
[5] Japan Patent Office. (2010). JP2011-123456.
